(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2010 (30.09.2010)

PCT

(10) International Publication Number
WO 2010/111018 A8

(51) International Patent Classification:
A61K 39/00 (2006.01) *C12P 21/08* (2006.01)

(21) International Application Number:
PCT/US2010/026429

(22) International Filing Date:
5 March 2010 (05.03.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/158,143 6 March 2009 (06.03.2009) US

(71) Applicants *(for all designated States except US)*: **AGENSYS, INC.** [US/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **SEATTLE GENETICS, INC.** [US/US]; 21823 30th Drive S.E., Bothell, WA 98021 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GUDAS, Jean** [US/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **JAKOBOVITS, Aya** [US/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **AN, Zili** [US/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **MORRISON, Robert, Kendall** [GB/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **MORRISON, Karen, Jane Meyrick** [GB/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **JIA, Xiao-Chi** [US/US]; 2225 Colorado Avenue, Santa Monica, CA 90404 (US). **BENJAMIN, Dennis** [US/US]; 21823 30th Drive S.E., Bothell, WA 98021 (US). **MOSER, Ruth** [US/US]; 21823 30th Drive S.E., Bothell, WA 98021 (US). **SENTER, Peter** [US/US]; 21823 30th Drive S.E., Bothell, WA 98021 (US).

(74) Agents: **MURASHIGE, Kate., H.** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
3 March 2011

(15) Information about Correction:
see Notice of 3 March 2011

(54) Title: ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS

(57) Abstract: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

WO 2010/111018 A8